SHANGHAI - Shenzhen-listed Nantong Jinghua Pharmaceutical has acquired exclusive China rights to two humanized monoclonal antibodies (mAbs) for cancer from New York-based Kadmon Corp. LLC. The move marks Jinghua’s first step in building a new drug pipeline to take part in the innovation transformation of the Chinese pharmaceutical industry.
Jinghua Aims To Transform Through Kadmon Biologics Alliance
China-listed Jinghua Pharmaceutical has tapped into developing biologic drug through investment and licensing agreement with US-based Kadmon, shifting from a traditional Chinese medicine maker to mAbs developer. The company has seen increasing competition and revenue drops in Chinese traditional medicine industry.